In a small corner of the Amazon, in Colombia, a group of scientists are working to treat ganoid lucidity with a combination of drugs, as they battle the invasive disease, dubbed Ganodermatitis Lucidus, (Gll).
The team, which includes researchers at the Universidad Nacional Autónoma de Colombia (UNAMCO), the Instituto Nacimiento de Tecnologia, and the Universidade Federal do Rio Grande do Sul (UFGR), has been trying to treat the disease for decades.
In order to treat Ganodermitis Lucidis (GML), scientists inject the drug with a specific protein known as RAGE (referred to in Spanish as ganodidylarginylarginyl) and try to mimic the symptoms of the disease in a mouse model.
The results are promising, but the team has some reservations.
In a paper published in the journal PLoS One, the scientists describe how they tested and compared the efficacy of two treatments.
One treatment is an anti-inflammatory drug that reduces inflammation and reduces the spread of the bacteria.
Another is a non-inflammatory, anti-inflammation drug, called tigecyclovir (TEG), which can be administered as a patch.
“The drug was effective in a variety of experimental models, including mice, rabbits, guinea pigs, and primates, and also in a guinea pig model,” explains the researchers, who also worked on the guinea-pig study.
“However, the drug was not effective in the human model, where the effects were similar to those seen in the guillemot models.”
In addition, the authors also reported that they did not find any difference between the two drugs.
The team also tested the drug on two other species of Ganodermaceae, and they found that the two treatments did not alter their behavior in any way.
The researchers also reported finding that, when compared to the drug, the combination of tigercycline and the anti-proliferative agent, CGP40, was the only drug that improved the mice’s cognitive function.
The scientists also used other methods to assess the effectiveness of the drug.
In mice, they found the drug significantly reduced the amount of the gut bacterium, Lactobacillus, that is known to be the cause of ganotrophiosis.
The drug also reduced the production of Bacteroides, a bacteria found in the intestines of the mice, which can lead to severe diarrhea.
The study was also done in rabbits.
The findings show that the combination therapy with tigernol and tigECP40, as well as a combination treatment with tIGEC, may be effective in reducing the severity of the symptoms and reducing the transmission of the bacterial infection.
The authors also noted that they have already used this combination in mice, and that they are looking to apply it to humans in the future.
The discovery was recently published in Nature Microbiology.
More information: “Treatment of Ganodidymedia lucidum by a combination drug and anti-gut bacteriophage.”
PLoS ONE DOI: 10.1371/journal.pone.0189064